LN-145 or LN-145-S1 in Treating Patients With Relapsed or Refractory Ovarian Cancer, Triple Negative Breast Cancer (TNBC), Anaplastic Thyroid Cancer, Osteosarcoma, or Other Bone and Soft Tissue Sarcomas
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Novartis
SpeciCare
SWOG Cancer Research Network
National Cancer Institute (NCI)
National Cancer Institute (NCI)